By KYIV. Jan 19 (Interfax-Ukraine) – The Darnitsa pharmaceutical company has registered in Poland a drug that is used in the complex treatment of acute and chronic heart failure, acute and chronic renal failure, nephrotic syndrome, liver disease and hypertension.
As the company reported in its press release, the drug was registered in accordance with EU requirements.
The company said that this drug is popular not only in neighboring Poland, but also in most EU countries, since these diseases are widespread among Europeans.
In Europe, hospitals purchase the drug through tender procedures.
In June 2023, Darnitsa registered one of its drugs in Australia, which is known as a country with some of the strictest regulatory rules in the world.
